nyuuzyou/wikis huggingface dataset:
Deferoxamine (Desferal)

==General information==
Class/mechanism: Iron chelating agent; chelates iron from ferritin and hemosiderin but not easily from transferrin. Does not combine with iron from hemoglobin and cytochromes. The chelate is soluble in water and is excreted by the kidney (as well as the bile), which causes urine to appear reddish.Deferoxamine (Desferal) package insert Deferoxamine (Desferal) package insert (locally hosted backup)
Route: IM, SC, IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. 
==Patient drug information==
*Deferoxamine (Desferal) patient drug information (UpToDate)Deferoxamine (Desferal) patient drug information (UpToDate)
==Also known as==
*Generic names: desferrioxamine B, desferoxamine B, DFO-B, DFOA, DFB
*Brand name: Desferal
==References==
Category:Drugs
Category:Intramuscular medications
Category:Intravenous medications
Category:Subcutaneous medications
Category:Hematology medications
Category:Chelators
Category:FDA approved in 1968
Defibrotide (Defitelio)

==General information==
Class/mechanism: Profibrinolytic. Defibrotide is a mixture of polydeoxyribonucleotide sodium salts made from porcine intestinal tissue. In vitro, it boosts enzymatic activity of plasmin to hydrolyze fibrin clots. Defibrotide increases tissue plasminogen activator (t-PA) and thrombomodulin expression while decreasing von Willebrand factor (vWF) and plasminogen activator inhibitor-1 (PAI-1) expression. Endothelial cell fibrinolysis is enchanced and endothelial cell activation is reduced. Defibrotide appears to limit damage caused by chemotherapy, tumor necrosis factor-α (TNF-α), serum starvation, and perfusion.Defibrotide (Defitelio) package insertDefibrotide (Defitelio) package insert (locally hosted backup)Defitelio manufacturer's website
Route: IV 
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Diseases for which it is used==
*Hepatic veno-occlusive disease (VOD), sinusoidal obstructive syndrome (SOS) with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT)
==Patient drug information==
*Brief patient counseling information available in the Defibrotide (Defitelio) package insert
==History of changes in FDA indication==
*2016-03-30: FDA approved for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstructive syndrome, with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).
==History of changes in EMA indication==
*2013-10-18: Initial authorization
*Uncertain date: Defitelio is indicated for the treatment of severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstructive syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy. It is indicated in adults and in adolescents, children and infants over 1 month of age.
==History of changes in PMDA indication==
*2019-06-18: Newly indicated for the treatment of sinusoidal obstruction syndrome (SOS) /hepatic veno-occlusive disease (VOD).
==Also known as==
*Generic name: polydeoxyribonucleotide sodium salt
*Brand name: Defitelio
==References==
Category:Drugs
Category:Intravenous medications
Category:Profibrinolytics
Category:Hepatic veno-occlusive disease medications
Category:EMA approved in 2013
Category:FDA approved in 2016
Category:PMDA approved in 2019
Degarelix (Firmagon)

==General information==
Class/mechanism: Gonadotropin-releasing hormone (GnRH) receptor antagonist. Reversibly binds to pituitary GnRH receptors, reducing the release of luteinizing hormone (LH) and follicle stimulation hormone (FSH), resulting in rapid androgen deprivation/decreased testosterone levels. There is no initial testosterone surge/flare with degarelix, in contrast to GnRH agonists.Degarelix (Firmagon) package insert Degarelix (Firmagon) package insert (locally hosted backup)Firmagon manufacturer's website
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. 
==Diseases for which it is used==
*Prostate cancer
==Patient drug information==
*Degarelix (Firmagon) package insert
*Degarelix (Firmagon) patient drug information (Chemocare)Degarelix (Firmagon) patient drug information (Chemocare)
*Degarelix (Firmagon) patient drug information (UpToDate)Degarelix (Firmagon) patient drug information (UpToDate)
==History of changes in FDA indication==
*2008-12-24: Approved for treatment of patients with advanced prostate cancer. (Based on CS21)
==History of changes in EMA indication==
*2009-02-17: Initial authorization as Firmagon. Firmagon is a gonadotrophin releasing hormone (GnRH) antagonist indicated for treatment of adult male patients with advanced hormone-dependent prostate cancer.
*2021-10-19: Extension of indication to include treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.
*2021-10-19: Extension of indication to include treatment as neo-adjuvant prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
==History of changes in Health Canada indication==
*2009-11-16: Initial notice of compliance for testosterone suppression in patients with advanced hormone-dependent prostate cancer in whom androgen deprivation is warranted.
==History of changes in PMDA indication==
*2012-06-29: Initial approval for the treatment of prostate cancer.
==Also known as==
*Code name: ASP-3550, FE-200486
*Generic name: degarelix acetate
*Brand name: Degafelix, Degalyn, Degapride, Degatide, Degarelix, Deghor, Degrinta, Firmagon, Gonax, Segarelix
==References==
Category:Drugs
Category:Subcutaneous medications
Category:GnRH antagonists
Category:Prostate cancer medications
Category:FDA approved in 2008
Category:EMA approved in 2009
Category:Health Canada approved in 2009
Category:PMDA approved in 2012
Denileukin diftitox (Ontak)

Ontak was discontinued in 2014; it is unclear if this medication is still available in the US under other branding; it is available in Japan as Remitoro.
==General information==
Class/mechanism: Recombinant diphtheria toxin fusion protein which binds with high affinity to IL-2 receptors. The fusion protein is internalized by receptor-mediated endocytosis and is cleaved, releasing the diphtheria toxin, which inhibits protein synthesis and causes cell death.Denileukin diftitox (Ontak) package insert Denileukin diftitox (Ontak) package insert (locally hosted backup)Ontak manufacturer's website
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. 
==Diseases for which it is used==
*Cutaneous T-cell lymphoma
*Peripheral T-cell lymphoma
==Patient drug information==
*Denileukin diftitox (Ontak) patient drug information (Chemocare)Denileukin diftitox (Ontak) patient drug information (Chemocare)
*Brief patient counseling information can be found on page 5 of the Denileukin diftitox (Ontak) package insert
*Denileukin diftitox (Ontak) patient drug information (UpToDate)Denileukin diftitox (Ontak) patient drug information (UpToDate)
==History of changes in FDA indication==
* 1999-02-05: Initial accelerated approval for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor. (Based on L4389-10)
**2008-10-15: Converted to regular approval for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor. (Based on L4389-11)
==History of changes in PMDA indication==
*2021-03-23: Newly indicated for the treatment of relapsed or refractory peripheral T-cell lymphoma and relapsed or refractory cutaneous T-cell lymphoma.
==Also known as==
*Code names: DAB(389)-interleukin-2, DAB389 interleukin-2, DAB389 interleukin-2 immunotoxin, DAB-IL2, LY-335348
*Brand name: Ontak, Remitoro
==References==
Category:Drugs
Category:Intravenous medications
Category:Protein expression-specific medications
Category:Anti-IL-2R immunotoxins
Category:Cutaneous T-cell lymphoma medications
Category:Peripheral T-cell lymphoma medications
Category:FDA approved in 1999
Category:Discontinued drugs
Denintuzumab mafodotin (SGN-CD19A)

==Mechanism of action==
From the NCI Drug Dictionary: An immunoconjugate consisting of an anti-CD19 monoclonal antibody conjugated to the auristatin derivative monomethyl auristatin F (MMAF), with potential antineoplastic activity. Upon administration of denintuzumab mafodotin, the antibody moiety targets the cell surface antigen CD19, found on a number of B-cell-derived cancers.
==Preliminary studies==
# Abstract: Andres Forero-Torres, Craig Moskowitz, Ranjana H. Advani, Bijal D. Shah, Ana Kostic, Tina M. Albertson, Larissa Sandalic, Baiteng Zhao, Michelle A. Fanale. Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL). J Clin Oncol 32:5s, 2014 (suppl; abstr 8505) link to original abstract
==Also known as==
*Code name: SGN-CD19A
Category:Drugs
Category:Intravenous medications
Category:Anti-CD19 antibody-drug conjugates
Category:Microtubule inhibitors
Category:Halted drugs
Dermatofibrosarcoma protuberans

Back to Top
Note: these are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.
Last updated on 2024-07-23:1 regimens on this page
2 variants on this page
=Guidelines=
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
==NCCN==
*NCCN Guidelines - Dermatofibrosarcoma Protuberans (DFSP)
**2014: Bichakjian et al. Dermatofibrosarcoma protuberans, version 1.2014 EuroPMC
**2012: Miller et al. Dermatofibrosarcoma protuberans. EuroPMC
**2007: Miller et al. Dermatofibrosarcoma protuberans. EuroPMC
**2004: Authors not listed. Dermatofibrosarcoma protuberans. Clinical practice guidelines in oncology. EuroPMC
=All lines of therapy=
==Imatinib monotherapy==
===Regimen variant #1, 400 mg/day===
Study 	Dates of enrollment	Evidence
Rutkowski et al. 2010 (SWOG S0345)	2005-2006 	Phase 2, fewer than 20 pts
====Targeted therapy====
*Imatinib (Gleevec) 400 mg PO once per day
48-week course
===Regimen variant #2, 800 mg/day===
Study 	Dates of enrollment	Evidence
Rutkowski et al. 2010 (EORTC 62027)	2004-2007 	Phase 2, fewer than 20 pts (RT)
====Targeted therapy====
*Imatinib (Gleevec) 400 mg PO twice per day
Continued indefinitely, unless complete (R0) surgical resection became possible
===References===
# EORTC 62027: Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM; EORTC Soft Tissue and Bone Sarcoma Group; SWOG. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010 Apr 1;28(10):1772-9. Epub 2010 Mar 1. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT00085475
# SWOG S0345: Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM; EORTC Soft Tissue and Bone Sarcoma Group; SWOG. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010 Apr 1;28(10):1772-9. Epub 2010 Mar 1. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT00084630
Category:Dermatofibrosarcoma protuberans regimens
Category:Disease-specific pages
Category:Soft tissue sarcomas
Desmoid tumor - null regimens

The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main desmoid tumor page for regimens that include active anticancer treatment.
=All lines of therapy=
==Placebo==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Gounder et al. 2018 (Alliance A091105)	2014-2016 	Phase 3 (C)	Sorafenib 	Shorter PFSPFS24: 36% vs 81%(HR 7.69, 95% CI 3.23-20.00)
Gounder et al. 2023 (DeFi) 	2019-05 to 2020-08 	Phase 3 (C)	Nirogacestat	Shorter PFSPFS24: 44% vs 76%(HR 3.45, 95% CI 1.82-6.67)
No active antineoplastic treatment.
===References===
# Alliance A091105: Gounder MM, Mahoney MR, Van Tine BA, Ravi V, Attia S, Deshpande HA, Gupta AA, Milhem MM, Conry RM, Movva S, Pishvaian MJ, Riedel RF, Sabagh T, Tap WD, Horvat N, Basch E, Schwartz LH, Maki RG, Agaram NP, Lefkowitz RA, Mazaheri Y, Yamashita R, Wright JJ, Dueck AC, Schwartz GK. Sorafenib for Advanced and Refractory Desmoid Tumors. N Engl J Med. 2018 Dec 20;379(25):2417-2428. link to original article link to PMC article EuroPMC NCT02066181
#DeFi: Gounder M, Ratan R, Alcindor T, Schöffski P, van der Graaf WT, Wilky BA, Riedel RF, Lim A, Smith LM, Moody S, Attia S, Chawla S, D'Amato G, Federman N, Merriam P, Van Tine BA, Vincenzi B, Benson C, Bui NQ, Chugh R, Tinoco G, Charlson J, Dileo P, Hartner L, Lapeire L, Mazzeo F, Palmerini E, Reichardt P, Stacchiotti S, Bailey HH, Burgess MA, Cote GM, Davis LE, Deshpande H, Gelderblom H, Grignani G, Loggers E, Philip T, Pressey JG, Kummar S, Kasper B. Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors. N Engl J Med. 2023 Mar 9;388(10):898-912. link to original article EuroPMC NCT03785964
Category:Desmoid tumor regimens
Category:Disease-specific pages
Category:Soft tissue sarcomas
Category:Null regimens
Desmopressin (DDAVP)

==General information==
Class/mechanism: Synthetic analog of vasopressin (ADH/antidiuretic hormone). In addition to its antidiuretic effects, also stimulates release of factor VIII and von Willebrand factor.Desmopressin (DDAVP tablet) package insert Desmopressin (DDAVP tablet) package insert (locally hosted backup)Desmopressin (DDAVP nasal) package insert Desmopressin (DDAVP nasal) package insert (locally hosted backup)Desmopressin (DDAVP injection) package insert Desmopressin (DDAVP injection) package insert (locally hosted backup)
Route: SC, IV, PO, nasal
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Patient drug information==
*Desmopressin (DDAVP nasal) package insert pages 9-10
*Desmopressin (DDAVP) patient drug information (UpToDate)Desmopressin (DDAVP) patient drug information (UpToDate)
==Authorized distributors==
The most current list of distributors can found at CSL Behring's website.CSL Behring's list of authorized Stimate distributors
*ABO Pharmaceuticals
*AmeriSource Bergen
*Bellco Drug Company
*Burlington Drug Company
*Capital Wholesale
*Cardinal Health
*D & K Healthcare
*Dakota Drug
*F. Dohmen Wholesale
*FFF Enterprises
*Frank W. Kerr Wholesale
*James W. Daly Wholesale
*Kinray
*Miami-Luken Inc.
*McKesson Plasma and Biologics
*McQueary Brothers
*N.C Mutual Wholesale
*Rochester Drug
*Smith Wholesale
*Whitmire Drug
*Value Drug
==Also known as==
*Brand names: DDAVP, DesmoMelt, Desmotabs, Desonap, Minirin, Stimate
==References==
Category:Drugs
Category:Nasal medications
Category:Intravenous medications
Category:Oral medications
Category:Subcutaneous medications
Category:Hematology medications
Category:Hemostasis medications
Category:Vasopressin analogs
Category:FDA approved in 1978
Dexchlorpheniramine (Polaramine)

==Mechanism of action==
Antihistamine (H1 antagonist), used to prevent or treat allergic side effects from chemotherapeutics and blood products.
==Also known as==
*Brand names: Oramin, Polaramine, Polmon, Topmine
Category:Drugs
Category:Oral medications
Category:Antihistamines
Category:FDA approved in 1981
Category:Discontinued drugs
Dexrazoxane (Zinecard)

==General information==
Class/mechanism: Intracellular chelating agent derived from EDTA. Mechanism not fully understood, but hypothesized to protect against anthracycline-caused cardiomyopathy by interfering with iron-mediated free radical generation. Also used in cases of anthracycline extravasation.Dexrazoxane (Zinecard) package insert Dexrazoxane (Zinecard) package insert (locally hosted backup)Zinecard manufacturer's websiteDexrazoxane (Totect) package insertTotect manufacturer's website
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Efficacy references==
# Mouridsen HT, Langer SW, Buter J, Eidtmann H, Rosti G, de Wit M, Knoblauch P, Rasmussen A, Dahlstrøm K, Jensen PB, Giaccone G. Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Ann Oncol. 2007 Mar;18(3):546-50. Epub 2006 Dec 21. EuroPMC
# POG 9404: Asselin BL, Devidas M, Chen L, Franco VI, Pullen J, Borowitz MJ, Hutchison RE, Ravindranath Y, Armenian SH, Camitta BM, Lipshultz SE. Cardioprotection and safety of dexrazoxane in patients treated for newly diagnosed T-cell acute lymphoblastic leukemia or advanced-stage lymphoblastic non-Hodgkin lymphoma: A report of the Children's Oncology Group randomized trial Pediatric Oncology Group 9404. J Clin Oncol. 2016 Mar 10;34(8):854-62. Epub 2015 Dec 23. link to original article link to PMC article EuroPMC
==Patient drug information==
*Dexrazoxane (Zinecard) patient drug information (Chemocare)Dexrazoxane (Zinecard) patient drug information (Chemocare)
*Dexrazoxane (Zinecard) patient drug information (UpToDate)Dexrazoxane (Zinecard) patient drug information (UpToDate)
==Also known as==
*Code names: ADR-529, ICRF-187
*Generic name: dexrazoxane hydrochloride
*Brand names: Cardioxane, Cyrdanax, Savene, Totect, Zinecard
==References==
Category:Drugs
Category:Intravenous medications
Category:Chemotherapy protective agents
Category:Chelators
Category:FDA approved in 1995
Diethylstilbestrol (DES)

==Diseases for which it was used==
*Breast cancer
*Prostate cancer
==Also known as==
*Generic names: DES, stilbestrol, stilboestrol
*Brand name: Desplex, Dibestrol, Stibrol, Stilbest
Category:Drugs
Category:Oral medications
Category:Endocrine therapeutic
Category:Breast cancer medications (historic)
Category:Prostate cancer medications (historic)
Category:FDA approved in 1941
Category:Discontinued drugs
Category:Stub
Dimetindene (Fenistil)

==General information==
Class/mechanism: first-generation antihistamine.
Route: PO/IV
Extravasation: unknown
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Diseases for which it is used==
No known antineoplastic properties. Used for prevention of reactions to blood products or biologics (e.g. monoclonal antibodies) as well as treatment of such reactions.
==Also known as==
*Generic name: dimethindene maleate
*Brand names: Fencil, Fenistil
Category:Drugs
Category:Oral medications
Category:Intravenous medications
Category:Antihistamines
Category:FDA approved in 1960
Dinaciclib (SCH-727965)

==Mechanism of action==
A cyclin dependent kinase inhibitor that selectively inhibits cyclin dependent kinases CDK1, CDK2, CDK5, CDK9, and CDK12.
==Preliminary data==
===Chronic lymphocytic leukemia===
# Flynn J, Jones J, Johnson AJ, Andritsos L, Maddocks K, Jaglowski S, Hessler J, Grever MR, Im E, Zhou H, Zhu Y, Zhang D, Small K, Bannerji R, Byrd JC. Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. Leukemia. 2015 Jul;29(7):1524-9. Epub 2015 Feb 24. link to original article link to PMC article PubMed
# Ghia P, Scarfò L, Perez S, Pathiraja K, Derosier M, Small K, McCrary Sisk C, Patton N. Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia. Blood. 2017 Mar 30;129(13):1876-1878. Epub 2017 Jan 26. link to original article PubMed
===Multiple myeloma===
# Kumar SK, LaPlant B, Chng WJ, Zonder J, Callander N, Fonseca R, Fruth B, Roy V, Erlichman C, Stewart AK. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single agent activity in patients with relapsed multiple myeloma. Blood. 2015 Jan 15;125(3):443-8. Epub 2014 Nov 13. link to original article PubMed
==Also known as==
*Code names: MK-7965, SCH-727965
Category:Drugs
Category:Intravenous medications
Category:CDK inhibitors
Category:Chronic lymphocytic leukemia medications (investigational)
Category:Multiple myeloma medications (investigational)
Category:Investigational drugs